BioMarin Pharmaceutical, Inc. (BMRN)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about BioMarin Pharmaceutical, Inc. (BMRN)
Go deeper and ask any question about BMRN
Company Performance
Current Price
as of Sep 17, 2024$70.55
P/E Ratio
53.26
Market Cap
$13.43B
Description
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Metrics
Overview
- HQSan Rafael, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerBMRN
- Price$70.55+0.99%
Trading Information
- Market Cap$13.43B
- Float98.74%
- Average Daily Volume (1m)2,277,459
- Average Daily Volume (3m)2,211,721
- EPS$1.36
Company
- Revenue$2.59B
- Rev Growth (1yr)19.18%
- Net Income$107.17M
- Gross Margin79.57%
- EBITDA Margin18.33%
- EBITDA$129.92M
- EV$16.38B
- EV/Revenue6.32
- P/E53.26
- P/S5.46
Documents
SEC Filings
Factset Street Account
Earnings Calls
Factset